Human Longevity Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
80
- Latest Deal Type
-
2ndary - Private
- Investors
-
10
Human Longevity General Information
Description
Developer of a biotechnology platform designed to combine genomic and phenotypic information to accelerate the understanding of human health. The company's platform addresses the age-related decline in endogenous stem cell function and concentrates on cancer, diabetes, obesity, heart and liver diseases, and dementia by combining deoxyribonucleic acid sequencing and expert analysis with machine learning, enabling people to shape their health and shift the practice of medicine from reactive to proactive technologies.
Contact Information
Website
www.humanlongevity.comCorporate Office
- 4570 Executive Drive
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 4570 Executive Drive
- Suite 100
- San Diego, CA 92121
- United States
Human Longevity Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 11. Later Stage VC (Series B) | 21-Aug-2024 | Completed | Generating Revenue | |||
| 10. Reverse Merger | 21-Jun-2022 | Cancelled | Generating Revenue | |||
| 9. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 8. Later Stage VC | 06-Nov-2019 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 01-Sep-2017 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series B2) | 01-Mar-2017 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 04-Apr-2016 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 04-Mar-2014 | $80M | $580M | Completed | Generating Revenue | |
| 3. Accelerator/Incubator | $500M | Completed | Generating Revenue |
Human Longevity Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-2 | 133,034,522 | $0.000100 | $0.26 | $0.26 | 1x | $0.26 | 16.55% | |
| Series A-1 | 7,964,602 | $0.000100 | $2.26 | $2.26 | 1x | $2.26 | 0.99% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Human Longevity Comparisons
Industry
Financing
Details
Human Longevity Competitors (13)
One of Human Longevity’s 13 competitors is I-gene (Biotechnology), a Corporation company based in Moscow, Russia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| I-gene (Biotechnology) | Corporation | Moscow, Russia | ||||
| Genuity Science | Formerly VC-backed | Dublin, Ireland | ||||
| MapMyGenome India | Venture Capital-Backed | Hyderabad, India | ||||
| OmeCare | Formerly VC-backed | San Diego, CA | ||||
| Juvenescence | Venture Capital-Backed | Dublin, Ireland |
Human Longevity Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Human Longevity Patents
Human Longevity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019356597-A1 | Multi-omic search engine for integrative analysis of cancer genomic and clinical data | Inactive | 12-Oct-2018 | ||
| CA-3115991-A1 | Multi-omic search engine for integrative analysis of cancer genomic and clinical data | Pending | 12-Oct-2018 | ||
| EP-3864659-A1 | Multi-omic search engine for integrative analysis of cancer genomic and clinical data | Pending | 12-Oct-2018 | ||
| US-20210319907-A1 | Multi-omic search engine for integrative analysis of cancer genomic and clinical data | Inactive | 12-Oct-2018 | ||
| WO-2020077352-A1 | Multi-omic search engine for integrative analysis of cancer genomic and clinical data | Inactive | 12-Oct-2018 | G16H50/20 |
Human Longevity Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Human Longevity Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BroadOak Capital Partners | Growth/Expansion | Minority | ||
| G Vision Capital | Venture Capital | Minority | ||
| Panacea Capital (California) | Venture Capital | Minority | ||
| Shin Ryoku Trust | Venture Capital | Minority | ||
| TVM Capital Healthcare Partners | PE/Buyout | Minority |
Human Longevity Investments & Acquisitions (9)
Human Longevity’s most recent deal was a Early Stage VC with WearLinq for . The deal was made on 21-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| WearLinq | 21-May-2024 | Early Stage VC | Monitoring Equipment | ||
| Floré | 29-Jun-2020 | Early Stage VC | Other Consumer Non-Durables | ||
| Solius | 13-May-2020 | Seed Round | Therapeutic Devices | ||
| DoctorsForMe.AI | 15-Jan-2020 | Merger/Acquisition | Information Services (B2C) | ||
| Brainkey | 12-Apr-2019 | Early Stage VC | Decision/Risk Analysis |
Human Longevity Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Human Longevity and Performance Impact Venture Fund | San Diego, CA | 2020 |
Human Longevity FAQs
-
When was Human Longevity founded?
Human Longevity was founded in 2013.
-
Where is Human Longevity headquartered?
Human Longevity is headquartered in San Diego, CA.
-
What is the size of Human Longevity?
Human Longevity has 80 total employees.
-
What industry is Human Longevity in?
Human Longevity’s primary industry is Other Healthcare Services.
-
Is Human Longevity a private or public company?
Human Longevity is a Private company.
-
What is Human Longevity’s current revenue?
The current revenue for Human Longevity is .
-
How much funding has Human Longevity raised over time?
Human Longevity has raised $1.07B.
-
Who are Human Longevity’s investors?
BroadOak Capital Partners, G Vision Capital, Panacea Capital (California), Shin Ryoku Trust, and TVM Capital Healthcare Partners are 5 of 10 investors who have invested in Human Longevity.
-
Who are Human Longevity’s competitors?
I-gene (Biotechnology), Genuity Science, MapMyGenome India, OmeCare, and Juvenescence are some of the 13 competitors of Human Longevity.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
